Security Reports > Clovis Oncology

Clovis Oncology
Data Breaches, Cyber Attacks and Security Report

https://clovisoncology.com  ᛫ 
Last updated July 12, 2020

Clovis Oncology Security Rating

${grade.letter}
${cstarScore}
/ 950

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Clovis Oncology is implementing good security practices.

Company Information

Company:
${companyName}
Valuation:
${marketCap}
Employees:
${employees}
Location:
${country}
CEO:
${ceo}

About Clovis Oncology

Rociletinib is a medication developed to treat non-small cell lung carcinomas with a specific mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.


Data Breaches and Security News


Security Report for Clovis Oncology

Want a security rating for your organization?

This report shows a preliminary security rating for Clovis Oncology. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.

Get a deeper scan

Related posts

Read more about the latest issues in cybersecurity

More security reports

Compare Clovis Oncology's security performance with other companies